Breaking News, Promotions & Moves

Agenus Taps Dr. José Iglesias as Chief Medical Affairs Officer

Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL).

Author Image

By: Charlie Sternberg

Associate Editor

Agenus Inc., an immune-oncology company, has appointed José Iglesias, M.D. as Chief Medical Affairs Officer. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Accès Compassionnel (AAC) program. BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters